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ABSTRACT
Thymomas, tumors that arise from epithelial cells of the thymus gland, are 
the most common neoplasms of the anterior mediastinum, with an incidence rate 
of approximately 2.5 per million/year. Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 
or CD152) exerts inhibitory activity on T cells, and since its oncogenic role in the 
progression of different types of tumors, it has emerged as a potential therapeutic 
target in cancer patients.
In this study, we assessed the expression of CTLA-4 both at mRNA and protein 
levels in paraffin embedded-tissues from patients with thymomas. Furthermore, we 
evaluated the relationship between CTLA-4 expression and the clinical-pathologic 
characteristics and prognosis in patients with thymomas. Sixty-eight patients with 
median age corresponding to 62 years were included in this analysis. Thymomas were 
classified accordingly to the WHO and Masaoka-Koga for histochemical analysis and 
for prognostic significance.
A statistical difference was found between CTLA-4 mRNA levels in human normal 
thymus compared with thymoma specimens. CTLA-4 expression was statistically 
found to progressively increase in A, B1, B2, AB and it was maximal in B3 thymomas. 
According to Masaoka-Koga pathological classification, CTLA-4 expression was lower 
in I, IIA and IIB, and higher in invasive III and IV stages. By confocal microscopy 
analysis we identified the expression of CTLA-4 both in tumor cells and in CD45+ 
tumor-infiltrating leukocytes, mainly in B3 and AB thymomas.
Finally, CTLA-4 overexpression significantly correlates with reduced overall 
survival in thymoma patients and in atypical thymoma subgroup, suggesting that it 
represents a negative prognostic factor.
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INTRODUCTION
Thymomas, tumors that arise from epithelial cells 
of the thymus gland, are the most common neoplasms 
of the anterior mediastinum, with an incidence rate of 
approximately 2.5 per million/year [1]. Thymomas are 
rare in patients under 25 years of age and show a wide age 
distribution, with a mean of incidence around 50–60 years 
of age, without a major sex predilection [1]. Although 
thymomas are, in general, indolent neoplasms, they are 
considered as malignant, irrespective to different subtypes.
Thymic neoplasms are divided according to the 
WHO classification [1], which is based on the premise 
that thymoma cells can belong to two histologic 
types: spindle/oval (designated as type “A”) or round/
epithelioid (designated as type “B”). The type B were 
additionally subclassified based on the proportional 
increase in infiltrating lymphocytes and emergence of 
atypia of the neoplastic epithelial cells into B1, B2 and 
B3 subtypes. Finally a C category (thymic carcinoma) 
displaying cytological features of malignancy, including 
marked atypia, nuclear pleomorphism and high mitotic 
activity is accounted [2–5]. The Masaoka-Koga stage 
classification distinguished thymic malignancies in 
not-invasive I and IIA and invasive IIB, IIIA, IIIB, IVA 
and IVB stages [6]. Furtherly, accordingly to Moran 
and Suster classification, a more simplified approach in 
classifying the thymic epithelial neoplasms based on the 
histologic grading in well-differentiated (A, AB, B1 and 
B2, typical thymoma), moderately differentiated (B3, 
atypical thymoma) and poorly differentiated (C, thymic 
carcinoma), has been proposed [6–10]. Type AB thymoma 
is not considered a mixed tumor of type A and type B 
thymomas, but a distinct type of thymoma derived from 
a mixture of type A- and type B-like component positive 
for E-cadherin and negative for vimentin or a mixture of 
type B-like components and metaplastic mesenchymal 
components, positive for vimentin and negative for 
E-cadherin [11]. Once a tumor has been assigned to a 
differentiation category of thymic epithelial neoplasms, 
reliable prognostication can be determined by clinical 
and pathological Masaoka-Koga staging of the lesions. 
However, in several cases, histologic classification, 
according to WHO and/or pathological Masaoka-Koga 
stage classifications, cannot be completely correlated 
with clinical outcome [12], so the need to identify new 
prognostic biomarkers. In addition, an association 
between myasthenia gravis (MG), a neuromuscular 
disorder characterized by a defective transmission of 
nerve impulses to muscles, and thymoma has been 
reported [13]. About forty percent of the thymoma 
patients had associated MG, and preoperative absence 
of MG has been considered an independent predictor of 
poorer overall survival (OS) [12]. This disease is caused 
by an autoimmune reaction against components of the 
neuromuscular junction on the post-synaptic membrane 
of the striated skeletal muscles [13] and it is present at 
first diagnosis in up to a third of thymoma patients [14].
Cytotoxic T lymphocyte antigen-4 (CTLA-4, 
CD152) is an immune checkpoint molecule and a CD28 
homologue that binds the ligands B7-1 (CD80) and B7-2 
(CD86) [15]. Human CTLA-4 is present as a full-length 
membrane-bound receptor and as a secreted soluble 
molecule [16, 17]. Both the two isoforms reduce T cell 
activation by forming a negative feedback to maintain 
immune self-tolerance and homeostasis. CTLA-4 
outcompetes CD28 for B7 ligands, attenuating the T cell 
response through the inhibition of IL-2 and blockage of 
cell cycle progression [18]. CTLA-4 is constitutively 
expressed at low levels on the surface of naïve, effector 
T (Teff) and regulatory T cells (Treg). The expression 
of CTLA-4 on Tregs reduces the levels of B7 ligands on 
antigen presenting cells. CTLA-4 has been also implicated 
in immune dysregulation of B cell chronic lymphocytic 
leukemia [19] and non Hodking’s lymphoma [20].
The CTLA-4 molecule is expressed on normal 
non-lymphoid cells including placental fibroblasts 
[21], cultured muscle cells [22], monocytes [23] and 
mature dendritic cells [24]. In addition, it has been 
demonstrated that CTLA-4 is constitutively expressed 
not only in leukemia cells [25], but also in several types 
of tumor-derived cell lines including breast, colon, 
renal, lung, ovarian, uterine, bladder carcinoma, osteo/
rabdomyosarcoma, neuroblastoma and melanoma [26] and 
in cancer tissues, such as osteosarcomas [26], non-small 
cell lung [27] and breast [28], nasopharyngeal [29], gastric 
[30] and esophageal carcinomas [31] and mesotheliomas 
[32]. Finally, CTLA-4 gene polymorphisms have been 
associated to increased susceptibility to multiple types 
of cancer such as breast [33], melanoma [34] gastric and 
colon cancers [35] and cervical carcinomas [36].
At present, the expression of CTLA-4 was only 
taken into account for the MG profiling indicating an 
association between different CTLA-4 single nucleotide 
variants and susceptibility to disease [37].
Thus, in this study, we assessed the expression 
of CTLA-4 both at mRNA and protein levels in fixed 
paraffin-embedded thymoma tissues. Furthermore, we also 
evaluated the correlation between CTLA-4 expression and 




The complete list of patient characteristics is 
summarized in Table 1. Clinico-pathologic analyses 
according to WHO and Masaoka-Koga classifications are 
reported in Supplementary Tables 1 and 2, respectively. 
Extra-capsular invasive behavior was evidenced mainly 
in B2, B3 and C thymoma types (71, 83 and 100%, 
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respectively) (Supplementary Table 1). In addition, 
concomitant MG is present in about 1/3 of thymoma 
patients, mainly in B2-B3 thymoma types (59 and 50%, 
respectively). In regard to extra-capsular invasion, it was 
more evident in IIB, III and IV Masaoka-Koga stages 
(Supplementary Table 2).
CTLA-4 mRNA expression in thymoma tissues
The CTLA-4 mRNA expression was evaluated 
in thymoma specimens (n = 63/68), two different 
batches of RNA from human normal thymus and, as 
control, peripheral blood mononuclear cells (PBMCs), 
from healthy donors, unstimulated and stimulated 
with phorbol 12-myristate 13-acetate (PMA). Given 
the small number of thymoma type C samples, the 
expression of CTLA-4 mRNA was not evaluated in 
these specimens. CTLA-4 mRNA was expressed at low 
levels in normal thymus, unstimulated PBMCs, whereas 
increased CTLA-4 levels (8-fold) were evidenced in 
PMA-stimulated PBMCs, upon PMA stimulation, as 
previously described [23, 38] (Figure 1A). Moreover, 
independently of WHO classification, CTLA-4 
mRNA levels were very low in normal thymus respect 
to thymoma tissues (Figure 1B). Quantitative real 
time polymerase chain reaction (qRT-PCR) analysis 
also identified that the CTLA-4 mRNA expression 
progressively increase from A, B1, B2, AB and B3, with 
the higher levels in B3 type thymomas, as evaluated by 
statistical analysis (Figure 1B). Then, analyzing CTLA-
4 expression in thymomas according to Masaoka-Koga 
stage, a significant difference between I vs IIA, IIB, III 
and IV, IIA and IIB vs III or IV stages was observed. No 
major differences were found comparing IIA vs IIB or III 
vs IV grade (Figure 1C). Finally, according to Moran and 
Suster classification [5, 7, 8, 10] significant difference in 
CTLA-4 mRNA expression were evidenced comparing 
typical (A, B1, B2 and AB types) vs atypical (B3 type) 
thymomas, with the last expressing very higher CTLA-4 
mRNA levels respect to typical thymomas (Figure 1D). 
Finally, we evaluated whether adjuvant chemo-, radio-
therapy or MG may affect the expression of CTLA-4 
mRNA in thymoma patients (Supplementary Figure 1). 
We found higher CTLA-4 mRNA levels in thymoma 
patients undergoing adjuvant radiotherapy compared 
to untreated patients. No major differences in CTLA-4 
expression were observed in untreated vs chemotherapy-
administered thymoma patients and in MG vs non-MG 
thymoma patients.
Expression of CTLA-4 protein in tumor cells 
and tumor-infiltrating leukocytes (TILs) from 
thymoma tissues
The results obtained in thymoma tissues by qRT-
PCR prompted us to evaluate the expression of CTLA-
4 protein in the different histological type of thymomas 
by immunohistochemistry (IHC) and semi-quantitative 
analysis. CTLA-4 immunoreactivity was found in all 
thymoma type sections and the percentage of CTLA-4+ 
cells progressively increase from A, B1, B2, AB and B3, 
with the highest levels in B3 type thymomas (Figure 2A 
and 2B). No reactivity was found in tissue sections used 
as negative control incubated with the omission of 
primary Ab (Figure 2A). Moreover, although the number 
of thymoma type C samples was limited to be included 
in the statistical analysis, the immunohistochemistry was 
performed and showed a strong CTLA-4 staining in these 
specimens (Supplementary Figure 2).
Table 1: Patient demographics and clinical features
PATIENTS N=68 (100%)
GENDER
 M 33 (48.5%)
 F 35 (51.5%)
AGE (years)
 Range 21-81
 21-45 14 (20.6%)
 46-59 19 (27.9%)
 >60 35 (51.5%)
 Median 62
Myasthenia Gravis
 Yes 22 (32.4%)
 No 46 (67.6%)
Tumor Histology
 A 11 (16.2%)
 AB 17 (25.0%)
 B1 6 (8.8%)
 B2 17 (25.0%)
 B3 12 (17.6%)
 C 5 (7.4%)
TUMOR SIZE
 < 5 cm 28 (41.2%)
 > 5 cm 40 (58.8%)
Invasion
 Yes 55 (80.9%)
 Capsular 24 (43.6%)
 Extracapsular 31 (56.4%)
 No 11 (16.2%)
 ND 2 (2.9%)
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Since B1, B2 and B3 types are characterized by 
a proportional increase in TILs, the co-expression of 
CD45 and CTLA-4 antigens was evaluated using the 
anti-human CD45 and anti-CTLA-4 monoclonal Abs by 
confocal microscopy. CTLA-4 expression progressively 
increased in B1, B2, AB and B3 thymomas, whereas 
negligible CTLA-4 protein expression was found in type 
A thymoma as demonstrated by the Fluorescence Intensity 
confirming the IHC data (Figure 3A and 3B). Moreover, in 
tumor cells, CTLA-4 protein localised in the membrane, 
cytoplasm or both in a scattered pattern (Figure 3A). In 
addition, we found in accordance with previous reports 
[3, 4, 9], that TILs progressively increase from B1 to 
B3 and AB thymomas with about 20.1% and 14.6% of 
CTLA-4 positive cells being CD45 positive in B3 and 
AB thymomas respectively (Figure 3C). Finally, in AB 
thymomas the expression of vimentin and CTLA-4 in 
tumor cells was evaluated using an anti-human vimentin 
and anti-CTLA-4 mAbs. A mixture of less represented 
CTLA-4+/Vimentin+ tumor cells as well as a more 
represented CTLA-4+/Vimentin- tumor cells was observed 
in AB thymoma sections (Figure 4).
Correlation between clinico-pathologic and 
prognostic parameters, CTLA-4 tumor expression 
and overall survival in thymoma patients
Survival curves were calculated according to 
univariate analysis (Table 2) and the Kaplan–Meier 
method by evaluating the age (< 60 vs > 60 years), 
sex, MG, invasion phenotype, invasion localization 
(capsular vs extra-capsular), tumor dimensions < 5 cm 
or > 5 cm, radicality and CTLA-4 mRNA expression. In 
regard to CTLA-4 expression, patients were divided into 
two groups showing low < 0.5 (n = 15 specimens) and 
high > 0.5 (n = 48 specimens) CTLA-4 level. CTLA-4 
mRNA expression reached significance for survival (p = 
0.0107) (Figure 5A) with in CTLA-4low OS = 188.31 vs 
CTLA-4high OS = 119.50 months. In addition, atypical 
histological type thymoma (OS = 65.73 months) (Figure 
5B) showed a significant (p = 0.0055) reduced survival 
respect to typical thymoma (OS = 188.22 months) 
confirming that high CTLA-4 expression in atypical 
thymoma (Figure 1D) is associated with negative 
prognosis. Age > 60 and tumor dimension > 5 cm were 
Figure 1: CTLA-4 expression on normal human thymus, lymphocytes and thymoma tissues. (A) CTLA-4 mRNA expression 
was evaluated by qRT-PCR in normal human thymus and PBMCs treated or not with PMA. CTLA-4 mRNA levels were normalized 
for GAPDH expression. Data are expressed as fold mean ± SD. *p<0.05 vs PBMCs, #p<0.05 vs PBMC, normal thymus -1 and normal 
thymus -2. (B) CTLA-4 mRNA expression levels distribution according to WHO classification; statistical analysis was performed using 
non-parametric Kruskal-Wallis with Dunn’s multiple comparisons test. Data are expressed as fold mean ± SD, *p<0.05 vs normal thymus-2; 
#p<0.05 vs A, B1, B2 and AB. (C) CTLA-4 mRNA expression levels distribution according to Masaoka-Koga classification; statistical 
analysis was performed by non-parametric Kruskal-Wallis with Dunn’s multiple comparisons test. Data are expressed as fold mean ± 
SD, *p<0.05 vs I, #p<.0.05 vs IIA or IIB. (D) CTLA-4 mRNA expression level distribution according to Moran and Suster classification; 
statistical analysis was performed using non-parametric Kruskal-Wallis with Dunn’s multiple comparisons test. Data are expressed as fold 
mean ± SD, *p<0.05 typical vs atypical thymomas.
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positively correlated (p = 0.0002, with OS < 60 = 196.83 
vs > 60 = 119.50 months; p = 0.0429, with OS < 5cm 
= 209.88 vs > 5cm = 137.72 months, respectively) 
(Figure 6A and 6B). The presence of concomitant MG 
in thymoma patients approximates the significance (p 
= 0.0889, OS = 188.32 vs non MG = 153.66 months) 
(Figure 6C). No correlation for sex, tumor invasion, 
extra-capsular tumor invasion (Figure 6D) and radicality 
(Figure 6E) was evidenced. Thus, the higher CTLA-4 
mRNA expression, age > 60 years and tumor dimension 
> 5 cm strongly correlated with short survival in total 
thymoma group and in atypical thymoma subgroup. 
Additionally we performed a multivariate analysis based 
on the Cox regression model to test the influence of 
CTLA-4 mRNA expression, age > 60 years and tumor 
dimensions > 5 cm on the survival of thymoma patients. 
We found that CTLA-4 overexpression, age > 60 years 
and typical vs atypical histological subtypes retained 
their prognostic negative significance in thymoma 
patients (p = 0.0235, 0.0071 and 0.0041, respectively) 
(Table 2).
DISCUSSION
Thymic epithelial tumors (TETs) are uncommon 
neoplasms with a wide range of anatomical, clinical, 
histological and molecular malignant entities. At present, 
the management of TETs within clinical practice is based 
on a multimodal therapeutic strategy including surgery, 
chemotherapy and radiotherapy with a multidisciplinary 
approach and prognostic evaluation mainly based on 
Masaoka-Koga staging and WHO classification [39–41].
Novel strategies are needed, especially for 
refractory, recurrent thymic tumors after first-line 
chemotherapy failure. The investigation of molecular 
profiling and the analyses of immunological markers in 
thymic tumors could also allow determining potentially 
new targets.
To our knowledge, this is the first study 
demonstrating that elevated CTLA-4 tumor expression 
in thymoma patients correlates with poor prognosis and 
shorter OS. At present, CTLA-4 association to thymomas 
has only been taken into account for the MG profiling. 
Figure 2: CTLA-4 protein expression in different subtypes of thymoma tissues. (A) Sections of A, B1, B2, B3 and AB 
thymomas A were processed for hematoxylin and eosin staining (right column) and for CTLA-4 (left column) by immunohistochemistry. 
Sections of thymoma B1 thymomas processed for immunohistochemistry without incubation of primary antibody, were used as negative 
control. Calibration bar: 25 μm. (B) The percentage of CTLA-4 positively stained cells was determined in all samples according to the 
staining intensity by the NIS Software. Data represents the mean ± SD. *p<0.05 vs A; #p<0.05 vs B1, B2 and AB.
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Figure 3: Expression of CTLA-4 in tumor cells and CD45+ TILs from thymoma specimens. Confocal microscopy analysis 
was performed in thymoma tissues double-stained with anti-CTLA-4 and anti-CD45 mAbs, followed by Alexa Fluor 488- and Alexa Fluor 
594-conjugated secondary Abs, respectively. Control = merge of secondary Abs without the incubation of the primary Abs. Data shown are 
representative of one out of three separate experiments. Calibration bar: 25 μm. (B) The CTLA-4 Fluorescence intensity was evaluated in 
all samples by using the NIS Software. Data represent the mean ± SD. *p<0.05 vs (A); #p<0.05 vs B1, B2 and AB. (C) The percentage of 
CTLA-4+CD45+cells was evaluated in B2, B3 and AB samples according to the double fluorescence intensity by using the NIS Software 
and considering the total CTLA-4+ cells as 100%. Data represent the mean ± SD. *p<0.05 vs total CTLA-4+ cells.
Figure 4: Expression of vimentin and CTLA-4 in AB subtype thymomas. Confocal microscopy analysis was performed 
in thymoma AB specimens double-stained with anti-vimentin and anti-CTLA-4 mAbs, followed by Alexa Fluor 488- and Alexa Fluor 
594-conjugated secondary Abs, respectively. Control = merge of secondary Abs without the incubation of the primary Abs. Data shown are 
representative of one out of three separate experiments. Calibration bar: 25 μm.
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In particular, single nucleotide polymorphisms (SNPs) 
of CTLA-4 seem to be associated with the manifestation 
of MG in patients with thymoma. SNPs in position 49 in 
patients expressing high CTLA-4 levels, in particular SNP 
+49 A/A and SNP +49 A/G showed a bad prognosis and 
reduced OS [42–44].
Herein, we analyzed the expression of CTLA-4 
in thymoma patients with different WHO histological 
types and Masaoka-Koga stages. We found that CTLA-
4 expression was significantly higher in all thymoma 
WHO types, compared with healthy thymus. We also 
stated that CTLA-4 gene expression was lower in A and 
B1, progressively increased in B2 and AB and was higher 
in B3 type thymomas, representing this histological type, 
the atypical thymoma subgroup, according to Moran and 
Suster classification [5, 7, 8, 10]. Thus, following both 
the WHO or Moran and Suster classifications the highest 
CTLA-4 value was evidenced in atypical B3 thymomas.
In parallel, by qRT-PCR, we observed a higher 
CTLA-4 expression in more advanced Masaoka-Koga 
grade IIB, III and IV compared to I and IIA, suggesting 
that CTLA-4 overexpression may be related to tumor 
aggressiveness. In regard to AB thymomas, a mixture of 
less represented mesenchymal CTLA-4+/Vimentin+ tumor 
cells as well as a more represented CTLA-4+/Vimentin- 
tumor cells was observed in AB thymoma sections. The 
metaplastic CTLA-4+/Vimentin+ tumor cells likely derived 
from an epithelial mesenchymal transition process and 
trans-differentiation of spindle cells that have up-regulated 
mesenchymal markers [11].
According to previously reported data [12], Kaplan-
Mayer and univariate analysis evidenced in thymoma 
patients with concomitant MG higher OS and good 
prognosis compared to non-MG patients. Autoimmunity 
and malignancy frequently coexist and they may share 
etiological and pathogenic mechanisms [45]. A sort of 
protective autoimmunity has been reported to improve the 
survival of cancer patients [46]; however at the other hand, 
better OS observed in MG patients could also depend to 
early discovery of MG vs non-MG thymomas, allowing a 
better survival of thymoma patients [47].
More importantly, our results suggest that in 
thymoma patients higher CTLA-4 mRNA expression 
represents a negative prognostic marker. In fact, the 
increase of CTLA-4 gene expression in total thymoma 
group and in B3 subgroup was associated with a shorter 
survival. In a multivariate Cox proportional hazards 
regression model, high CTLA-4 levels both in total 
and atypical thymoma, as well as age > 60 and tumor 
dimension > 5 cm, confirm their significance as negative 
prognostic factor for survival. Overall, tumor-associated 
CTLA-4 could promotes tumor progression by inhibiting 
the anti-tumor T cell immunity, inducing tumor-specific 
T cell apoptosis or impairing cytokine production and T 
cell-mediated cytotoxicity [48].
We also found that CTLA-4 is expressed not only 
in tumor cells, but also in CD45 leukocytes infiltrating 
the thymomas. In immune cells, CTLA-4 has been found 
to be expressed in B lymphocytes [17], monocytes [49], 
and activated effector CD4+ and CD8+ T cells, as well as 
constitutively expressed on a subset of regulatory Treg 
[50] participating in the co-stimulatory activation of naïve 
T cells or depletion of activated T cells [51]. Antigen 
specific activation of naïve T cells induces the expression 
of cytokines such as interferon-γ, which in turn triggers 
CTLA-4 expression in surrounding immune and tumor 
cells. The presence of Treg in tumor microenvironment 
has been associated with poor outcomes in patients 
with cancers [52]. In this regard, confocal microscopy 
analysis evidenced CTLA-4+CD45+ TILs, likely Treg 
lymphocytes, in the tumor microenvironment of B3 and 
AB thymomas, showing reduced OS. Thus the presence 
of CD45+CTLA-4+ TILs, in tumor environment of 
B3 and AB thymomas, might contribute to the profile 
of immunosuppression allowing unrestrained tumor 
progression due to impaired host immune surveillance.
The clinical implication of CTLA-4 expression in 
tumors or immune cells in the tumor microenvironment 
Figure 5: Kaplan-Meier curves of survival according to CTLA-4 expression and histological types. (A) Kaplan-Meier 
plot was evaluated stratifying patients according to CTLA-4 expression levels. (B) Kaplan-Meier plot was evaluated stratifying patients 
according to typical vs atypical thymoma subtypes.
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is still controversial, and the potential for CTLA-4 as 
prognostic and therapeutic marker has been complicated 
by differences in study population, methods and 
histological tumor types [53–54]. In agree with our 
results, univariate analysis demonstrates that higher 
tumor CTLA-4 expression is associated with shorter 
OS and poorer prognosis of patients with esophageal 
cancers [31]. Moreover in human breast cancer, high 
tumor CTLA-4 expression is associated with shorted 
OS, disease-free survival and worse prognosis [28]. 
The OS, failure-free survival and distant failure free 
survival rate was lower in nasopharyngeal carcinoma 
(NPC) patients and NPC patients with high tumor 
CTLA-4 levels [29]. By contrast, the CTLA-4 
expression positively correlates with less advanced 
stage, intestinal type and well/moderately differentiated 
gastric adenocarcinoma [30] and represents a favorable 
prognostic factor in mesothelioma tissues, serum and 
Figure 6: Kaplan-Meier curves of survival according to age, Myasthenia Gravis, tumor size, extra-capsular invasion 
and radicality. (A) Kaplan-Meier plot was evaluated stratifying patients by age. (B) Kaplan-Meier plot was evaluated stratifying patients 
according to the tumor size. (C) Kaplan-Meier plot was evaluated stratifying patients according to the presence or not of Miastenia Gravis. 
(D) Kaplan-Meier plot was evaluated stratifying patients according to the presence of extra-capsular invasion or capsular invasion. (E) 
Kaplan-Meier plot was evaluated stratifying patients according to the radicality. R0: complete tumor resection; R1: incomplete microscopic 
tumor resection; R2: incomplete macroscopic tumor resection.
Table 2: Univariate and multivariate analysis of overall survival in thymomas (Tumor CTLA-4 expression)
Variable Univariate analyses Multivariate analyses
HR 95% CI P-value HR 95% CI P-value
-Tumor CTLA-4 expression 2.9987 1.4599 0.0107* 2.9301 1.2351 0.0235*
-Typical/Atypical 0.2170 0.029 0.0055* 0.1490 1.7970 0.0041*
-Myastenia Gravis 0.4874 0.2158 0.0889ns 0.6116 0.7171 0.1919ns
-Age 0.2145 0.0612 0.0002* 0.2971 1.6236 0.0071*
-Sex 1.4669 0.2516 0.4048ns 2.9641 0.4203 0.9807ns
-Tumor invasion 0.4150 0.6388 0.1745ns 0.4390 0.3312 0.5793ns
-Tumor dimension 0.4035 0.1634 0.0429* 0.3240 0.3814 0.6237ns
-Metastatic spread 1.4670 0.5050 0.5145ns 2.0072 0.4367 0.5149ns
-Radicality 1.7180 0.9976 0.0878ns 1.9703 0.9024 0.1531ns
Abbreviations: HR, hazard ratio; CI, confidence interval.
*p < 0.05; ns = not significant.
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pleural effusion [32]. Finally, a higher frequency of 
CTLA-4 overexpression was found in non-squamous 
as respect to squamous non-small cell lung cancer, 
and a reduced death rate was found in CTLA-4 
overexpressing tumors [27].
Different cellular and murine models have 
been used to demonstrate that drugs inducing CTLA-
4 blockade, used alone or in combination with other 
therapeutic interventions, improves endogenous 
responses to several tumor types, leading to tumor cell 
death when utilized. Treatment of CTLA-4 expressing 
tumor cell lines with recombinant forms of the CTLA-4 
ligands CD80 and CD86 induced caspase-8-dependent 
apoptosis and the level of apoptotic tumor cells was 
reduced by soluble CTLA-4 and anti-CTLA-4 single-
chain variable fragment antibodies [26]. Preclinical 
findings have been translated into the clinical 
development of two different CTLA-4 blocking Ab, 
ipilimumab (IPI) and tremelimumab [55–56]. Thus, 
antibody-mediated blockade of CTLA-4 may ultimately 
prove useful, either alone or in combination with other 
immune-based manipulations, have been successful 
employed in patients with metastatic melanoma, 
advanced prostate and pancreatic carcinomas [57–59], 
refractory B-cell non-Hodgkin lymphoma [60], early 
stage breast cancer [61] and we suggested it could be 
also used to improve the effectiveness of thymoma 
therapy. Moreover, in the view of increasing numbers 
of effective drugs available for treatment of thymoma, 
upfront identification of patients who are more likely 
to fail or benefit of treatment is the major unmet 
need. Regarding the use of IPI, thymoma patients 
showing high CTLA-4 expression could be benefit 
of immunotherapy with IPI. Thus, the higher CTLA-
4 expression not only in Teff and Treg cells, but also 
in tumor cells, might facilitate tumor cellular lysis 
through an IPI-dependent cell-mediated cytoxicity by 
FcRγ expressing immune cells, such as monocytes 
for Treg [62] or natural killer and lymphocytes Tγδ 
for tumor cells [63]. In addition, CTLA-4 could also 
serve as a predictive biomarker for selecting the 
most appropriate therapy for thymoma patients and 
maximizing the clinical benefit with minimal toxicity. 
Other immunosuppressive co-stimulatory molecules, 
including PD-L1, PD-L2 remain under investigation in 
the context of thymomas and may similarly facilitate 
the downregulation of anti-tumor immune responses. In 
this regard, as demonstrated for PD-L1 immunotherapy, 
increased CTLA-4 expression where observed in 
patients undergoing adjuvant radiotherapy [64].
Overall, further clinical studies may be warranted 
to completely address the meaning of CTLA-4 expression 
in tumor cells and tumor-infiltrating leukocytes and/or 
of others co-stimulatory molecules to define the most 
effective treatment and prognosis in thymoma patients.
MATERIALS AND METHODS
Patients and thymoma specimens
The study population consisted of all consecutive 
patients aged 18 years or older (n = 68) who underwent 
surgery for thymomas from 1993 to 2013 at Università 
Politecnica delle Marche–Azienda Ospedaliero-
Universitaria Ospedali Riuniti Umberto I – Lancisi – 
Salesi, Ancona, Italy. Other inclusion criteria included 
Eastern Cooperative Oncology Group performance status 
≤ 2, adequate organ functions and no serious concomitant 
disease. All patients gave their consent and the local 
Ethical Committee approved the study (214439942015 
approval number).
Paraffin-embedded tissues were prepared from 
surgically removed thymomas. Thick sections (5-7 μm) of 
thymoma tissues were collected and processed. Thymoma 
sections were stained with hematoxylin and eosin (H&E) 
and classified according to WHO histologic classification, 
in type A, AB, B1, B2, B3 and C, as well as Masaoka-
Koga classification in I, IIA, IIB, III and IV stages.
Stimulation of PBMCs with PMA
PBMCs were isolated from whole blood of 
healthy donors (ASUR 9, Macerata) by density gradient 
centrifugation on a Lympholyte solution (Cederlane, 
Burlington, Canada). After washing, purified cells were 
counted and then 107 cells (1×106/ml) were treated with 
5 ng/ml of PMA (Sigma Aldrich, St Louis, MO, USA) 
for 48 h at 37°C, 5% CO2 and 95% of humidity in RPMI 
1640 (Euroclone Ltd, Devon, UK) supplemented with 
10% heat-inactivated fetal calf serum 2mM L-glutamine, 
100 IU/ml of penicillin and 100 μg/ml of streptomycin 
(Euroclone Ltd). Untreated cells were used as control.
Tissues, RNA extraction and reverse 
transcription
Total RNA from unstimulated and PMA-stimulated 
PBMCs was extracted by RNeasy Mini Kit (QIAGEN, 
Milan, Italy) whereas from fixed paraffin-embedded 
tissue slices by using “RNeasy® FFPE” kit (Qiagen). 
Two different lots of RNA from human normal thymus 
were purchased from Zyagen (San Diego, USA) and 
Clontech (Mountain Valley, CA). All RNA samples were 
eluted in the appropriate buffer and their concentration 
and purity evaluated by 260/280nm measurement. Five 
hundred nanograms of RNA were subjected to reverse 
transcription in a total volume of 25 μl using the high-
capacity cDNA archive kit (PE Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s 
instructions. Five microliters of the resulting cDNA 
products were pre-amplified for 10 cycles using kit “RT2 
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PreAMP cDNA Synthesis” (QIAGEN). Two microliters 
of the resulting preAmp products was used as template for 
PCR quantification employing “RT2 qPCR Primer Assay” 
kit (QIAGEN).
Quantitative real time polymerase chain reaction 
(qRT-PCR)
qRT-PCR was performed by using IQ5 Multicolor 
real-time PCR detection system (BioRad, Hercules, CA, 
USA). The reaction mixture contained the RT2 SYBR® 
Green qPCR Mastermix (QIAGEN), human CTLA-4 and 
GAPDH primers (RT2 qPCR Primer Assay for Human 
CTLA-4 and GAPDH, QIAGEN). The PCR parameters 
were 10 min at 95°C followed by 40 cycles of 95°C 
for 15 s and 60°C for 40 s. All samples were assayed in 
triplicate in the same plate. The relative amount of target 
mRNA was calculated by the 2-ΔΔCt method, using GAPDH 
as a housekeeping gene.
Immunohistochemistry (IHC)
For IHC, sections were pretreated in microwave for 
10 min with Tris-HCl EDTA pH 9. After washes in PBS, 
sections were treated with 3% H2O2 for 20 min, washed, 
incubated for 1 h at room temperature with 3% bovine 
serum albumin and 0.3% Triton X-100 in PBS, and then 
overnight at 4°C with a mouse anti-CTLA-4 mAb (clone 
BNI3, isotype IgG2a, 1:100) (Novus Biologicals, Littleton, 
CO, USA). Thereafter, slides were incubated for 30 min at 
room temperature with a biotinylated secondary antibody, 
rinsed, and exposed for 30 min to the streptavidin–
biotin complex (ABC Elite kit; Vinci Biochem, Vinci, 
Italy). Immunoreactivity was detected by the addition of 
diaminobenzidine (Vector, USA) for 5 min, counterstained 
with hematoxylin for 30 seconds and embedded in 
mounting medium. Four random fields of each tissue 
specimen were analyzed under 20X magnification using 
the Olympus BX51 Microscope and the Image J software 
(National Institutes of Health, Bethesda, MD, USA). 
The percentage of CTLA-4 positively stained cells was 
determined in all samples according to the staining 
intensity by the NIS Software (Nikon, Otawara, Japan). 
For each tumor specimens positive cells were counted in 
10-fields of 0,5 mm2.
Confocal microscope analysis
Sections were pre-treated in microwave for 10 min 
with Tris-HCl EDTA pH 9. After 2 washes in PBS sections 
were treated with 3% H2O2 for 20 min, washed, treated 
for 6 min with potassium permanganate solution (KMnO4 
0.06%) and incubated for 1 h at room temperature with 
3% bovine serum albumin and 0.3% Triton X-100 in PBS. 
After that sections were incubated overnight at 4°C with 
mouse anti-CTLA-4 mAb (Novus Biologicals, Littleton, 
USA, clone BNI3, isotype IgG2a, 1:25) followed by 
anti-mouse IgG AlexaFluor 488 secondary Ab (Thermo 
Fisher Scientific corporation, Waltham, USA, 1:100) for 
60 min at 37°C, then overnight at 4°C with mouse anti-
human CD45 mAb (Dako, Glostrup, Denmark, clone 
2B11+PD7/26, isotype IgG1, 1:50) followed by anti-
mouse IgG1 AlexaFluor 594 secondary Ab (Thermo Fisher 
Scientific corporation, 1:100) for 60 min at 37°C. In some 
experiments sections were incubated overnight at 4°C with 
mouse anti-CTLA-4 mAb (1:25) followed by anti-mouse 
IgG2a AlexaFluor 594 secondary Ab (Thermo Fisher 
Scientific corporation, 1:100) for 60 min at 37°C, then 
overnight at 4°C with mouse anti-human Vimentin mAb 
(Sigma, Saint Louis, USA, clone V9, isotype IgG1, 1:50) 
followed by anti-mouse IgG AlexaFluor 488 secondary 
Ab (Thermo Fisher Scientific corporation, 1:100) for 60 
min at 37°C. Finally sections were embedded in mounting 
medium. Four random fields of each tissue specimen were 
analysed under 40X magnification using the Confocal 
Microscopy Nikon C2plus and the NIS software (Nikon, 
Otawara, Japan). The CTLA-4 Fluorescence Intensity 
was evaluated in all samples by using the NIS Software. 
For each tumor specimens fluorescence intensity was 
evaluated in 10-fields of 0,5 mm2. Moreover, to assess 
the contribution of CD45+ cells and tumor cells in the 
CTLA-4 expression, the percentage of CD45+CTLA-4+ 
was evaluated in B2, B3 and AB samples according to the 
Fluorescence intensity and considering the total CTLA-4+ 
cells as 100% by the NIS Software.
Statistical analysis
Statistical analysis was perfomed using One Way-
Anova and Two Way-Anova with Bonferroni’s post-test. 
In addition, the non-parametric Kruskal-Wallis with 
Dunn’s multiple comparisons was used to analyze CTLA-
4 expression between the different WHO thymoma type 
histological and Masaoka-Koga stages.
The significant contribute of adjuvant chemo- 
or radiotherapy on the CTLA-4 mRNA expression in 
thymoma patients was evaluated by unpaired t’ test, 
p < 0.05.
OS were estimated using Kaplan-Meier method with 
Rothman’s 95% confidence intervals (CI) and compared 
across the groups using the log-rank test. We determined by 
Relative Operating Characteristic (ROC) curve analysis the 
CTLA-4 mRNA value that best discriminated between good 
and poor survival. Then, patients were divided for age, sex, 
invasiveness, extra-capsular or capsular invasion, tumor 
dimension more or less 5 cm, concomitant myasthenia 
gravis, WHO histological types and on the basis of CTLA-4 
mRNA expression in CTLA-4low≤ 0.5 and High CTLA-4high 
> 0.5 (evaluated by ROC analysis), and typical and atypical 
thymomas. Overall survival was defined as the interval 
between the date of surgery to death or last follow-up visit. 
These groups were subjected to univariate and multivariate 
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survival analysis. For survival analysis, the Kaplan-Meier 
method was used. For univariate analysis of significance, 
the long-rank test or Cox analysis was used. The Cox 
proportional hazards model was used for multivariate 
analysis. p< 0.05 was considered as statistically significant. 
Statistical analysis was performed with MedCalc package 
(MedCalc® v16.4.3).
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